Drug Profile
Protein C Activator
Alternative Names: PCALatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Anticoagulants
- Mechanism of Action Protein C stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 12 Jun 1998 New profile
- 12 Jun 1998 Preclinical development for Thrombosis in USA (Unknown route)